

22-FEB-2010 10:39 FROM NSTDA

TO 00115712732885

P.01

Docket No.: ThaiBiotec004
(PATENT)**CERTIFICATE OF MAILING BY "EXPRESS MAIL Carrier"**

I hereby certify that this correspondence is being deposited with the Express Mail Carrier, in an envelope addressed to: Mail Stop ISSUE FEE, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on: Feb 22, 2010

Total of 5 pages**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: National Science and Technology Development Agency

Application No.: 10/626,585

Filed Date: 07/25/2003

Art Unit: #1648

For Title: Dengue virus mutant strain MBU 01-2002

Examiner Name: CHEN, Stacy Brown

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir,

In response to the Notice of Comply which is attached to Notice of Allowance and Fee(s) Due of Date, 02/03/2010, please accept the above identified application as indicated below. The deadline to respond to this notice is 05/03/2010. As such, this response is timely filed.

With this amendment, I send:

1. a substitute computer readable form (CRF) copy of the "Sequence Listing".
2. a paper copy of the "Sequence Listing".
3. a copy of Notice to Comply.

The substitute computer readable form (CRF) copy of the "Sequence Listing" includes SEQ ID NO: 2 and 3 which are part of the original disclosure but inadvertently omitted from the previous submitted CRF and paper sequence listing.

The content of the paper and computer readable copies are the same and, where applicable, includes no new matter.

Dated: February 22, 2010

Respectfully submitted,

By Nuttina Netsuwan

Nuttina Netsuwan

Page 1 of 1

Notice to Comply	Application No. 10626585	Applicant(s) KEE LAPANG ET AL.
	Examiner Stacy B. Chen	Art Unit 1648
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES <p>Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p> <ul style="list-style-type: none"> <input type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1214 OG 82 (June 23, 1998). <input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). <input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). <input type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." <input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). <input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). <input checked="" type="checkbox"/> 7. Other: <p>Applicant Must Provide:</p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". <input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. <input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). <p>For questions regarding compliance to these requirements, please contact:</p> <ul style="list-style-type: none"> For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510 PatentIn Software Program Support Technical Assistance, 1-866-217-9197 or 703-305-3028 or 571-272-6845 PatentIn Software Is Available At www.USPTO.gov <p>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</p>		
/Stacy B Chen/ Primary Examiner, Art Unit 1648	See attached Office action for details.	